Related Experiment Video
Updated: Sep 20, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cemiplimab in the treatment of metastatic basal cell carcinoma
1Department of Dermatology, Georgetown University School of Medicine, Washington, DC, USA.
Abstract:
Metastatic basal cell carcinoma (mBCC) is a rare but aggressive form of skin cancer that poses significant therapeutic challenges. Historically, systemic treatment options were limited, with hedgehog pathway inhibitors (HHIs) providing modest efficacy, but poor tolerability long term. This review explores cemiplimab, an immune checkpoint inhibitor targeting PD-1, as a novel therapeutic agent for mBCC. We examine its pharmacologic profile, clinical efficacy in clinical trials, safety and tolerability, and real-world performance. A comprehensive literature review was conducted using PubMed and clinical trial registries to assess cemiplimab's role in mBCC treatment, including its comparison to HHIs and potential in combination or neoadjuvant strategies. Cemiplimab has emerged as a transformative therapy for patients with mBCC who are intolerant to or have progressed on HHIs. Despite lower response rates compared to cutaneous squamous cell carcinoma, cemiplimab offers meaningful and durable disease control with a favorable safety profile and preservation of quality of life. Ongoing research into predictive biomarkers, neoadjuvant use, and combination regimens may further enhance its clinical utility.
Insights
Cemiplimab offers a new treatment for metastatic basal cell carcinoma (mBCC) for patients who cannot tolerate or have not responded to prior therapies. This PD-1 inhibitor provides durable disease control with a good safety profile, improving quality of life.
Area of Science:
- Oncology
- Dermatology
- Immunotherapy
Background:
- Metastatic basal cell carcinoma (mBCC) is a rare, aggressive skin cancer with limited treatment options.
- Hedgehog pathway inhibitors (HHIs) have shown modest efficacy but poor long-term tolerability in mBCC.
- Novel therapeutic strategies are needed for patients with advanced mBCC.
Purpose of the Study:
- To review the role of cemiplimab, a PD-1 inhibitor, in treating mBCC.
- To evaluate cemiplimab's efficacy, safety, and real-world performance.
- To compare cemiplimab with existing treatments like HHIs.
Main Methods:
- Comprehensive literature review of PubMed and clinical trial registries.
- Assessment of cemiplimab's pharmacologic profile, clinical trial data, and real-world evidence.
- Analysis of treatment outcomes, safety, and quality of life in mBCC patients.
Main Results:
- Cemiplimab is a transformative therapy for mBCC patients progressing on or intolerant to HHIs.
- It demonstrates meaningful and durable disease control.
- Cemiplimab offers a favorable safety profile and preserves quality of life, despite lower response rates than in cutaneous squamous cell carcinoma.
Conclusions:
- Cemiplimab represents a significant advancement in mBCC treatment.
- It provides a valuable option for patients with limited alternatives.
- Future research may optimize its use through biomarkers, neoadjuvant strategies, and combination therapies.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...